Who makes TRL345, a human monoclonal antibody?

TRL345, a human monoclonal antibody is developed by Trellis Bioscience LLC.

What development phase is TRL345, a human monoclonal antibody in?

TRL345, a human monoclonal antibody is in Phase 1.

Last reviewed 2026-04-19 · How we verify

TRL345, a human monoclonal antibody

Trellis Bioscience LLC · Phase 1 active Small molecule

At a glance

Generic name	TRL345, a human monoclonal antibody
Sponsor	Trellis Bioscience LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TRL345, a human monoclonal antibody CI brief — competitive landscape report
TRL345, a human monoclonal antibody updates RSS · CI watch RSS
Trellis Bioscience LLC portfolio CI